Historical eye on IPF: a cohort study redefining the mortality scenario

Area of Science:

• Pulmonary Medicine
• Clinical Research
• Epidemiology

Background:

• Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with limited treatment options.
• Recent advancements include therapies that slow IPF progression and may reduce mortality.
• Understanding real-world outcomes is crucial for optimizing patient care.

Purpose of the Study:

• To evaluate changes in IPF patient survival over the past 15 years in a real-life setting.
• To identify factors influencing IPF survival and treatment effectiveness.
• To assess the impact of antifibrotic therapy on IPF prognosis.

Main Methods:

• An observational study of 634 consecutive IPF patients diagnosed and treated between 2002 and 2016.
• Survival analysis and time-dependent Cox regression models were used.
• Propensity score matching estimated the effect of antifibrotic treatment.

Main Results:

• A significant mortality shift was observed around 2012 (HR 0.58).
• Antifibrotic treatment significantly reduced all-cause mortality, hospitalizations, and acute exacerbations.
• Lung cancer, hospitalizations, and acute exacerbations were significant negative prognostic factors.

Conclusions:

• Antifibrotic drugs significantly improve IPF patient outcomes, including survival, hospitalizations, and exacerbations.
• The introduction of cryobiopsy and antifibrotics has improved IPF prognosis and early detection.
• Real-world data confirms the substantial benefit of antifibrotic therapy in IPF management.